OncoSec Medical Incorporated · OTC:ONCSQ

OncoSec Medical — Investor Presentation (April 2023)

33 slides from OncoSec Medical's investor presentation, April 2023

  1. Slide 1: Corporate Update

    Corporate Update Non-Confidential Presentation April 2023

  2. Slide 2: Risk Factors and Forward-Looking Statements

    Risk Factors and Forward-Looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Com

  3. Slide 3: Awakening the immune system to eradicate cancer

    Awakening the immune system to eradicate cancer • Proprietary TAVO™ electroporation platform to elicit tumor-directed immune cell activation by stimulating the patient’s immune system without neoantigen delivery • Intra-tumoral delivery of interleukin 12 plasmid to cutaneous, subcutaneous and nodal

  4. Slide 4: OncoSec as a future leader of immuno-oncology therapy

    OncoSec as a future leader of immuno-oncology therapy Addressing unmet clinical needs by leveraging innovative intratumoral drug delivery Vision • We aspire to awaken the immune system to eradicate cancer and restore patients’ lives. Mission • Provide safe and effective solutions for cancer patients

  5. Slide 5: TAVO-EP platform designed to address key clinical unmet needs

    TAVO™-EP platform designed to address key clinical unmet needs • Unique intratumoral delivery applicable to cutaneous, Plasmid Electrode Gene subcutaneous, and nodal lesions 1 Injection 2 Insertion 3 Delivery • Demonstrated clinical activity for patients who have progressed on checkpoint inhibitors

  6. Slide 6: TAVO-EP plus KEYTRUDA - rationale for neoadjuvant melanoma

    TAVO™-EP plus KEYTRUDA® - rationale for neoadjuvant melanoma Going beyond immune checkpoint inhibitors and cancer vaccines, neoadjuvant melanoma represents promising option for patients with advanced melanoma1 • TAVO™-EP in the neoadjuvant setting offers a novel “personalized off-the-shelf therapeut

  7. Slide 7: The IO market driven by checkpoint inhibitors is growing rapidly

    The IO market driven by checkpoint inhibitors is growing rapidly Global Market Analysis and Forecast of Immuno-Oncology (IO) Approaches • Immuno-oncology (IO) approaches have 160 $143 B demonstrated significant, durable response 140 rates in a broad range of cancer types 120 Market Value ($B) CAGR 2

  8. Slide 8: Despite IO success, great unmet need remains in melanoma

    Despite IO success, great unmet need remains in melanoma Primary Resistance Secondary Resistance Most patients receive PD-1 mono- Among initial PD-1 responders, or combination therapy in first ~40% acquire resistance and line, yet 40 – 65% fail to respond1 progress within 5 years2 Key Unmet Needs Po

  9. Slide 9: Cancer vaccines aim to induce cancer immunity to close ICI gap

    Cancer vaccines aim to induce cancer immunity to close ICI gap • Cancer vaccines induce cancer immunity by educating immune effector cells to recognize selected tumor neoantigens or shared tumor-associated antigens provided as therapeutic modality • Personalized vaccines deliver autologous cancer an

  10. Slide 10: TAVO-EP IL-12 in situ vaccination to awaken the immune system

    Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP IL-12 in situ vaccination to awaken the immune system TAVO™ Cancer antigen TAA-presenting presenting APC APC ● ● ● Tumor ● ● cell ● ●● APC-mediated T cell activation ● in presence of IL-12 Draining lymph node Local release of tumor TAA-specific antig

  11. Slide 11: TAVO-EP has substantial clinical activity and safety data

    TAVO™-EP has substantial clinical activity and safety data • TAVO™-EP has been studied in clinical trials as mono- and combination therapy • TAVO™-EP was administered in most trials as 3 treatments per cycle in 6-week cycles • TAVO™-EP has been administered to more than 230 melanoma patients and ove

  12. Slide 12: Sharpened focus on melanoma and potential in other tumor types

    Melanoma: Neoadjuvant Melanoma: Advanced Triple Negative Breast Sharpened focus on melanoma and potential in other tumor types Regimen Trial Indication Partner Phase 1 Phase 2 Pivotal TAVO™ + OMS-104 Neoadjuvant Resectable Locally / recruiting Key Focus Nivolumab Phase 2 IST1 Regionally Advanced Mel

  13. Slide 13: Neoadjuvant melanoma therapy is gaining traction

    Melanoma: Neoadjuvant Melanoma: Advanced Neoadjuvant melanoma therapy is gaining traction… Southwest Oncology Group (SWOG) trial S1801 Phase 2, n= 313 • Pembrolizumab monotherapy (200 mg IV, Q3W) − Neoadjuvant (3 doses) and adjuvant (15 doses) vs. − Adjuvant (18 doses) • Primary endpoint EFS: − Land

  14. Slide 14: But not all patients benefit from neoadjuvant ICI combinations

    Melanoma: Neoadjuvant Melanoma: Advanced …but not all patients benefit from neoadjuvant ICI combinations OpACIN-neo trial (Phase 2, n=89) • Ipilimumab plus nivolumab (various dose regimens) • IFN-g signature and tumor mutational burden (TMB) in baseline tumors predicted better clinical outcomes. − P

  15. Slide 15: SITC 2022 Neoadjuvant Immunotherapy with Intratumoral TAVO plus EP and Nivolumab

    SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (TAVO) plus Electroporation (EP) in Combination with Intravenous Nivolumab in Patients with Operable Locoregionally Advanced Melanoma 1Ahmad A Tarhini, MD, PhD; 1Zeynep Eroglu, MD

  16. Slide 16: Neoadjuvant melanoma Phase 2 IST design and endpoints

    SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced Neoadjuvant melanoma Phase 2 IST* design and endpoints • Primary Endpoint: complete pathologic response (pCR) rate • Secondary Endpoints: Near-complete (major) pathologic response (pMR), radiological/clinical preoperative response rate, relapse free

  17. Slide 17: Bulky tumors disappear with treatment

    SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced Bulky tumors disappear with treatment Day 1 Day 8 Day 28 Day 85 (Cycle 1) (Cycle 1) (Cycle 2 Day 1) (right before surgery) RECIST v1.1 CR Pathologic CR 17

  18. Slide 18: High pathological major response rate with TAVO-EP + nivolumab

    SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced High pathological major response rate with TAVO™-EP + nivolumab Patient Disease Baseline Tumor No. of TAVO-EP No. of Nivo Cycles Radiological Preoperative Pathological Response‡ # Stage Biomarkers Full treatment = 6-9* Full treatment = 3 RECIST v1.1

  19. Slide 19: TAVO-EP Phase 2 neoadjuvant IST: predictive biomarkers

    Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP Phase 2 neoadjuvant IST: predictive biomarkers Baseline biomarkers predicting no or limited responses to anti-PD-1 mAb in majority of patients • Tumor infiltrating lymphocytes (TIL) are essential for anti-tumor immune responses by producing cytokines

  20. Slide 20: Inflammatory biomarker changes as early signs of clinical activity

    Melanoma: Neoadjuvant Melanoma: Advanced Inflammatory biomarker changes as early signs of clinical activity Peritumoral CD8+ CD8+ TIL 100 100 (within inflammatory population) 1 (non-responder) 80 80 Predictive biomarker signals change with treatment 2 (peritumoral) Enrolled patients (n=15); % CD8+ 3

  21. Slide 21: Summary of TAVO-EP Phase 2 IST in neoadjuvant melanoma

    SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced Summary of TAVO™-EP Phase 2 IST* in neoadjuvant melanoma • Intratumoral TAVO™-EP in combination with nivolumab in neoadjuvant melanoma exhibits encouraging clinical activity and a favorable safety profile • Pathologic complete response (pCR) rate 66

  22. Slide 22: TAVO-EP melanoma neoadjuvant summary

    Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP melanoma neoadjuvant summary Challenges Opportunities • ICI followed by surgery is not approved but may become SOC • Currently no approved therapies • Ipi/nivo has ~50% pathological complete response rate (pCR), • Patients start with accessible disea

  23. Slide 23: OncoSec neoadjuvant melanoma Phase 2 randomized trial design

    Melanoma: Neoadjuvant Melanoma: Advanced OncoSec neoadjuvant melanoma Phase 2 randomized trial design Pembrolizumab ± TAVO™-EP Neoadjuvant Definitive Surgery Adjuvant Phase Phase Phase N = 3-15 patients Run-In Surgery & 3 wks 3 wks 3 wks 3 wks Run-In Stage Resectable locally- Select Arm A dosing reg

  24. Slide 24: Run-In Design to assess TAVO-EP dosing regimen for Ph2 RCT

    Melanoma: Neoadjuvant Melanoma: Advanced Run-In Design to assess TAVO™-EP dosing regimen for Ph2 RCT PLANNING & FDA MEETING RUN-IN STAGE RANDOMIZATION 1H2023 4-10 months to interim data read-out 5 years • Ad Board meetings April 2023 • FDA meeting to discuss May 2023 − Study design D1 TAVO™-EP Patho

  25. Slide 25: TAVO-EP Phase 2 neoadjuvant melanoma trial (draft design)

    Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP Phase 2 neoadjuvant melanoma trial (draft design) Key eligibility criteria: Resectable stage III (B-D), surgery surgery accessible for electroporation TAVO + total subjects SOC adjuvant pembrolizumab (Q6W) N = 84 (1:1) pembro Stratification factors:

  26. Slide 26: KEYNOTE-695 Phase 2 in PD-1 refractory melanoma overview

    Melanoma: Neoadjuvant Melanoma: Advanced KEYNOTE-695 Phase 2 in PD-1 refractory melanoma overview Key Eligibility • Stage III/IV melanoma, target N = 152, ~30 global sites TAVO + pembrolizumab Survival Follow-up • ≥12 weeks of anti-PD-1 therapy, with documented disease progression within 12 weeks of

  27. Slide 27: KEYNOTE-695 Phase 2: Cohort 1a BICR summary

    Melanoma: Neoadjuvant Melanoma: Advanced KEYNOTE-695 Phase 2: Cohort 1a BICR summary • The primary endpoint of KEYNOTE-695, overall response rate (ORR) by blinded independent central review (BICR), was not met. BICR ORR1 of 10.2% (95% CI 5.00, 17.97%), including 4 CR and 6 PR, did not achieve the pr

  28. Slide 28: TAVO-EP 2023 milestones

    Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP 2023 milestones • Discussions with Regulatory Agencies regarding melanoma neoadjuvant [May 2023] • TAVO™-EP Phase 2 RCT in neoadjuvant melanoma initiation [4Q2023] • TAVO™-EP Phase 2 IST in neoadjuvant melanoma data update at upcoming medical meeting

  29. Slide 29: Global intratumoral cancer therapy market growth

    Global intratumoral cancer therapy market growth • Several independent studies show that the intratumoral cancer therapy market grows rapidly ⁻ monoclonal antibodies, vaccines, checkpoint Inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others (left panel)

  30. Slide 30: OncoSec beyond TAVO-EP: Visceral Lesion Applicator (VLA)

    OncoSec beyond TAVO™-EP: Visceral Lesion Applicator (VLA) VLA Organ Plasmid Gene (preclinical prototype) 1 Entry 2 Injection 3 Delivery 1.27mm DIAMET ER INSULAT OR RING BEVELED T IP SIDE INJECT ION PORT S • Applicable to solid tumors located deep inside the body through our unique intra-tumoral deli

  31. Slide 31: Investment opportunity

    Investment opportunity Differentiated Best-in-class Robust Development Intra-tumoral Platform Therapeutic Potential Strategy TAVO™ designed to Experienced overcome key immuno- Neoadjuvant Melanoma management team and therapy shortcomings, with encouraging key strategic partnerships with improved saf

  32. Slide 32: Experienced industry leaders with track record of success

    Experienced industry leaders with track record of success Leadership Team Board of Directors Linda Shi, M.D. Robert H. Arch, Ph.D Chair George Chi Robert H. Arch, Ph.D. President and Chief Financial Officer Director Chief Executive Officer Stephany Foster, M.B.A. Director Bridget O’Keeffe, Ph.D Robe

  33. Slide 33: Thank You

    ®)oncosec IMMUNOTHERAPIES THANK YOU!

OncoSec Medical — Investor Presentation (April 2023) on 6ix